Document is current

Article History

Received: 22 February 2024

Accepted: 26 August 2024

First Online: 7 September 2024

Declarations

:

: This is a retrospective study. IRB approval for this study was obtained and consent from each participant is not applicable.

: VOV, CW, SB, KT: No conflicts of interest to declare. AGJ: Speakers Bureau: Rigel. OC: Research Funding: Syntrix Pharmaceuticals. EP: Research Funding: Bristol Myers Squibb, Syntrix Pharmaceuticals, Kura, Incyte; Honoraria: Taiho, Stemline, Blueprint. AK: Research Support: Protagonist, Blueprint Medicines Corporation, GSK - Sierra Oncology, Prelude Pharmaceuticals, Bristol Myers Squibb, Morphosys; Consultancy: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma; Honoraria: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma; Speakers Bureau: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma. RK: Consultancy: Servier, AbbVie, Geron, Acceleron Pharma, Taiho Oncology, Novartis, Jazz Pharmaceuticals, Bristol Myers Squibb; Honoraria: Servier, AbbVie, CTI BioPharma, Innovent, PharmaEssentia, Takeda, Jazz Pharmaceuticals, Bristol Myers Squibb; Speakers Bureau: Servier, AbbVie, Jazz Pharmaceuticals; Advisory board: CTI BioPharma, Taiho Oncology, PharmaEssentia, Takeda, Novartis, Bristol Myers Squibb; Speakers Bureau: Bristol Myers Squibb; Research Funding: Bristol Myers Squibb. JEL: Consultancy: Dedham Group, Jasper Therapeutics, Astellas, Dava Oncology, Novartis, Agios/Servio, Boxer Capital, Jazz, BerGenBio, Millenium Pharma/Takeda, ElevateBio Management, Daiichi Sankyo, AbbVie, Servier; Research Funding: Syntrix Pharmaceuticals, Celgene/ Bristol Myers Squibb. DAS: Advisory Board: Intellia, Aprea, Syndax, Bristol Myers Squibb, Nemucore, Agios, AbbVie, Kite, Shattuck Labs, Novartis; Consultancy: Takeda, Novartis, Magenta; Speakers Bureau: Bristol Myers Squibb, Incyte; Research funding: Aprea, Syntrix Pharmaceuticals; Patents & Royalties: Lixte. KS: Consultancy: Pfizer, Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb; Advisory board: Pfizer, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb; Research funding: Pfizer, Syntrix Pharmaceuticals, Incyte; Honoraria: Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb.

: AGJ: Speakers Bureau: RigelVOV, CW, SB, KT: No conflicts of interest to declare.OC: Research Funding: Syntrix PharmaceuticalsEP: Research Funding: Bristol Myers Squibb, Syntrix Pharmaceuticals, Kura, Incyte; Honoraria: Taiho, Stemline, BlueprintAK: Research Support: Protagonist, Blueprint Medicines Corporation, GSK - Sierra Oncology, Prelude Pharmaceuticals, Bristol Myers Squibb, Morphosys; Consultancy: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma; Honoraria: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI Biopharma; Speakers Bureau: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, Pharmaessentia, CTI BiopharmaRK: Consultancy: Servier, AbbVie, Geron, Acceleron Pharma, Taiho Oncology, Novartis, Jazz Pharmaceuticals, Bristol Myers Squibb; Honoraria: Servier, AbbVie, CTI BioPharma, Innovent, PharmaEssentia, Takeda, Jazz Pharmaceuticals, Bristol Myers Squibb; Speakers Bureau: Servier, AbbVie, Jazz Pharmaceuticals; Advisory board: CTI BioPharma, Taiho Oncology, PharmaEssentia, Takeda, Novartis, Bristol Myers Squibb; Speakers Bureau: Bristol Myers Squibb; Research Funding: Bristol Myers Squibb.JEL: Consultancy: Dedham Group, Jasper Therapeutics, Astellas, Dava Oncology, Novartis, Agios/Servio, Boxer Capital, Jazz, BerGenBio, Millenium Pharma/Takeda, ElevateBio Management, Daiichi Sankyo, AbbVie, Servier; Research Funding: Syntrix Pharmaceuticals, Celgene/ Bristol Myers SquibbDAS: Advisory Board: Intellia, Aprea, Syndax, Bristol Myers Squibb, Nemucore, Agios, AbbVie, Kite, Shattuck Labs, Novartis; Consultancy: Takeda, Novartis, Magenta; Speakers Bureau: Bristol Myers Squibb, Incyte; Research funding: Aprea, Syntrix Pharmaceuticals; Patents & Royalties: LixteKS: Consultancy: Pfizer, Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb; Advisory board: Pfizer, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb; Research funding: Pfizer, Syntrix Pharmaceuticals, Incyte; Honoraria: Mablytics, berGenBio, Curis, Novartis, Gilead Sciences, Inc., AROG, Astellas, Bristol Myers Squibb.